A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

被引：2
|
作者：
Topp, Max S. [1 ]
Duell, Johannes [1 ]
Li, Jingjin [2 ]
Jankovic, Vladimir [2 ]
Lowy, Israel [2 ]
Sternberg, David [2 ]
Adriaens, Lieve [2 ]
Peterman, Mary [2 ]
Ambati, Srikanth R. [2 ]
Bannerji, Rajat [3 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126670
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4007
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
    Bender, Brendan C.
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael C.
    Chanu, Pascal
    BLOOD, 2023, 142
  • [22] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
    Neumann, F
    Martin, S
    Kronenwett, R
    Fischer, C
    Kondakci, M
    Kobbe, G
    Gattermann, N
    Haas, R
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [23] Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
    Liang, Aibin
    Ye, Shiguang
    Li, Ping
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Zhou, Lili
    Xu, Yangyang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Lan, Liping
    Lv, Xiaoteng
    Wei, Yutian
    Humphries, Michael
    Yao, Yihong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
    Patel, Krish
    Michot, Jean-Marie
    Chanan-Khan, Asher A.
    Salles, Gilles A.
    Cartron, Guillaume
    Peyrade, Frederic
    Bouabdallah, Reda
    Reid, Erin G.
    Thomas, Sheeba K.
    Wierda, William G.
    Liebowitz, David
    Pagel, John M.
    Ribrag, Vincent
    Saville, M. Wayne
    Johnson, Chelsea M.
    Ly, Thomas
    Phillips, Tycel J.
    BLOOD, 2019, 134
  • [25] A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
    Patel, Krish
    Riedell, Peter A.
    Tilly, Herve
    Ahmed, Sairah
    Michot, Jean-Marie
    Ghesquieres, Herve
    de Collela, Jean Marc Schiano
    Chanan-Khan, Asher
    Bouabdallah, Kamal
    Tessoulin, Benoit
    Iyengar, Sunil
    Long, Meixiao
    Clynes, Raphael
    Kanodia, Jitendra
    Bao, Lei
    Ding, Ying
    Jin, Jianhua
    Ainsworth, William B.
    Garcha, Raman
    Kye, Steve
    Phillips, Tycel J.
    BLOOD, 2022, 140 : 9470 - 9472
  • [26] A Phase I Study of the Anti-CD79b THIOMAB™-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
    Herrera, Alex F.
    Patel, Manish R.
    Burke, John M.
    Advani, Ranjana H.
    Cheson, Bruce D.
    Sharman, Jeffrey P.
    Penuel, Elicia
    Polson, Andrew G.
    Leng, Ning
    Li, Chunze
    Schuth, Eva
    Vaze, Anjali
    Samineni, Divya
    Elstrom, Rebecca
    Diefenbach, Catherine S.
    BLOOD, 2017, 130
  • [27] Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Sangha, Randeep
    Davies, Andrew
    Dang, Nam H.
    Ogura, Michinori
    MacDonald, David A.
    Volkert, Angela
    Ananthakrishnan, Revathi
    Luu, Kenneth
    Boni, Joseph P.
    Vandendries, Erik
    Goh, Yeow-Tee Y. T.
    BLOOD, 2013, 122 (21)
  • [28] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
  • [29] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Phase I Dose Esclation of Activated T Cells (ATC) Armed with Anti-CD3 x Anti-CD20 Bispecific Antibody (CD20Bi) after Stem Cell Transplant (SCT) In Non-Hodgkin's Lymphoma (NHL)
    Lum, Lawrence G.
    Ratanatharathorn, Voravit
    Thakur, Archana
    Al-Kadhimi, Zaid
    Skuba, Cassara
    Paul, Elyse N.
    Steele, Patricia A.
    Ayash, Lois
    Abidi, Muneer H.
    Uberti, Joseph P.
    BLOOD, 2010, 116 (21) : 216 - 217
12345